EF Hutton Reiterates Buy on Fate Therapeutics, Maintains $10 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Tony Butler has reiterated a 'Buy' rating on Fate Therapeutics (NASDAQ:FATE) and maintained a $10 price target.
August 09, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton has reiterated a 'Buy' rating on Fate Therapeutics and maintained a $10 price target, which could positively influence the stock's performance.
Analyst ratings and price targets can significantly influence a stock's performance. In this case, EF Hutton's reiteration of a 'Buy' rating and maintenance of a $10 price target for Fate Therapeutics indicates a positive outlook for the company, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100